Trending News

Palantir shares were down 7% in Tuesday’s midday session despite upbeat earnings as concerns about valuation gained momentum.

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

The recall includes certain model year 2020- 2025 Jeep Wrangler 4Xe and model year 2022-2026 Grand Cherokee 4Xe plug-in hybrid vehicles.

Timmer compared Nvidia’s valuations during the ongoing AI boom with those of Cisco, which was at the center of the dotcom bubble due to widespread adoption of the internet.

Brandt flagged the exhaustion gap beyond the 6,841.25 level

Baron Capital has been investing in Tesla since 2024 and will be voting for the package.

Karp noted that by shorting Palantir and Nvidia, Burry is actually shorting AI, while calling the practice of short selling egregious.

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Amazon stated that the transatlantic subsea fiber optic cable system will connect Maryland, U.S., and County Cork, Ireland.

This comes after a public fallout between Musk and President Donald Trump, after the Tesla CEO criticized the Trump administration’s “One Big Beautiful Bill” over spending concerns.

The company now expects adjusted EBITDA in Q4 to be $2.41 billion to $2.51 billion, marginally below an analyst estimate of $2.49 billion.

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.

In his weekly commentary, Siegel stated that the current rally in U.S. equities is driven by strong earnings from big technology companies in the latest quarter.

According to CnEVPost, Tesla China’s October sales numbers mark the lowest monthly number since May.

While Dow Jones futures were down by 0.72% at the time of writing, the S&P 500 futures fell 1.02%.

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.

The Palantir CEO stated that management’s efforts to improve the company are focused on the country, allied countries, and individual investors.

Norges Bank Investment Management, Tesla’s seventh-largest shareholder with a 1.12% stake, said it will vote against Musk’s proposed pay plan, citing concerns over its size, dilution, and reliance on one individual.

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Fund manager Louis Navellier expressed discomfort over the volatility despite the market’s upward momentum.

Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.

Samsung SDI is reportedly set to supply Tesla with lithium-iron phosphate batteries for its Megapack and Powerwall energy storage systems under a three-year deal worth about $2.1 billion.

Posting on X last week after a 2-year hiatus, big short fame Michael Burry warned of the AI bubble building and advised against playing it.

The announcement followed a strong third quarter, with total revenue up 12% year-over-year, led by a 92% jump in Ibsrela sales and steady Xphozah growth.

Rivian is set to report third-quarter results on Tuesday after market close, with analysts expecting revenue of about $1.5 billion and a narrower quarterly loss.

China proved to be a sore spot for Navitas, but the company sounded upbeat about its refocused efforts on high-revenue, high-margin businesses.

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

The Phase 3 ESSENCE study for Amondys 45 and Vyondys 53 failed to meet its primary endpoint, showing only modest numerical differences compared with placebo.

The AI-powered data analytics company reported record Q3 revenue, with CEO Alex Karp calling the YoY growth “otherworldly.”

CalPERS and several major U.S. funds said they will vote against Musk’s $1 trillion compensation package, citing governance and concentration-of-power risks.

The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles.

Black said in an X post on Monday that he expects the new compensation plan to receive 70% to 75% votes at Thursday’s annual meeting.

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million.

Pfizer filed the lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S, alleging that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action.

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively.

Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company.

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

The company said that the L6, launched in April 2024, has accumulated over 70,000 orders since its launch, and it is now taking steps to facilitate deliveries.

Chipotle Mexican Grill’s poor earnings report last week raised concerns for the restaurant industry.

Following an unseasonably strong October, the market is entering a seasonally robust November with solid year-to-date gains.

Meta analysts have expressed concerns about the company’s massive capital expenditure plan, although most expect the spending to solidify its AI prowess.

Nio posted a strong monthly sales performance in October, outpacing its major domestic peers.

Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.

The Omaha, Nebraska-based firm's operating earnings rose to $13.5 billion, compared with $10.1 billion in the year-ago quarter.

Wedbush analyst Dan Ives compared Apple’s position to that of Tesla, saying both companies are seen as lagging in AI but are poised to benefit from the technology’s next wave of consumer applications.

Staar said in the recent filing that starting October 15, its management engaged in private discussions with Alcon regarding the path forward with the proposed merger.

CEO Brian Armstrong said during Thursday’s earnings call that 264 institutions are now using the company’s developer platform.

The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents.

Bitcoin’s 17-year journey has been a tug-of-war between its decentralized, anti-establishment origins and growing institutional adoption.